Lab-Grown tumors could personalize bladder cancer chemo

NCT ID NCT07379255

Recruiting now Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether growing a patient's tumor cells in the lab (organoids) can help doctors choose the most effective chemotherapy after bladder cancer surgery. Researchers will compare survival rates of patients whose chemo was guided by organoid tests versus standard care. The goal is to improve outcomes for people with muscle-invasive bladder cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: organoid-guided chemotherapy selection
What this could lead to: If successful, this could make chemotherapy more personalized and effective for bladder cancer patients, potentially improving survival rates.
What could go wrong: This is an early-stage study with 266 participants, so results may not apply to everyone. Organoid testing is complex and may not always predict real patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.